DongKook Pharmaceutical Co (XKRX:086450) Long-Term Capital Lease Obligation : ₩4,859 Mil (As of Mar. 2025)

View and export this data going back to 2007. Start your Free Trial

What is DongKook Pharmaceutical Co Long-Term Capital Lease Obligation?

DongKook Pharmaceutical Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2025 was ₩4,859 Mil.

DongKook Pharmaceutical Co's quarterly Long-Term Capital Lease Obligation declined from Sep. 2024 (₩5,921 Mil) to Dec. 2024 (₩5,723 Mil) and declined from Dec. 2024 (₩5,723 Mil) to Mar. 2025 (₩4,859 Mil).

DongKook Pharmaceutical Co's annual Long-Term Capital Lease Obligation declined from Dec. 2022 (₩2,449 Mil) to Dec. 2023 (₩1,469 Mil) but then increased from Dec. 2023 (₩1,469 Mil) to Dec. 2024 (₩5,723 Mil).

DongKook Pharmaceutical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for DongKook Pharmaceutical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DongKook Pharmaceutical Co Long-Term Capital Lease Obligation Chart

DongKook Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

3,114.82

3,687.33

2,448.97

1,468.75

5,723.37

DongKook Pharmaceutical Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1,089.49	6,260.82	5,921.32	5,723.37	4,858.57

DongKook Pharmaceutical Co (XKRX:086450) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

DongKook Pharmaceutical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of DongKook Pharmaceutical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

DongKook Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DongKook Pharmaceutical Co Ltd (XKRX:086450) » Definitions » Long-Term Capital Lease Obligation

Traded in Other Exchanges

N/A

Address

Dongkook Building 997-8 Daechi 3-dong, Kangnam-gu, Seoul, KOR, 135-502

Website

http://www.dkpharm.co.kr

DongKook Pharmaceutical Co Ltd is a part of the healthcare industry based in Korea. Being a pharmaceutical company, its activities are focused on the research and development of drugs. The company produces superior medicines used favorably by consumers such as Madecassol, which is a drug for wounds and Oramedy, which is a drug for treating stomatitis. It also owns a prefilled syringe system in its second factory, through which it produces various kinds of ultramodern injection agents.

DongKook Pharmaceutical Co Headlines

No Headlines